A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
This achievement validates global demand and catapults Wanbury into high-growth acceleration
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Subscribe To Our Newsletter & Stay Updated
